Key global markets ended the week on a mixed note. China was the biggest gainer, up 2.5%, while France was the biggest loser with a loss of 1.8% on concerns after data showed the pace of growth in the eurozone's services and manufacturing sectors slowed more than expected Among the other Asian markets, India, Hong Kong and Singapore closed the week up 2%, 1.1% and 0.2% respectively. Japan was the only Asian market to end the week in the red, down 1.1%. All the European markets were in the red during the week. UK and Germany were down 0.9% and 1.1% respectively. In the Americas, Brazil was up 1.8% while US was down 0.7%. It may be noted that the close for all except India has been taken for September 30. India's closing for October 1 has been considered.
Source: Yahoo Finance |
Source: BSE |
TVS Motor Company also reported its highest-ever monthly sales of 188,005 units in September, a 30.8 % increase over the same month last year. TVS Motor's two-wheeler sales increased 29.6 % during the month to 184,783 units. Hero Honda's September sales were up by 18% YoY at 472,000 units while the sales of Bajaj Auto was up by 26% YoY to 353,000.
In news from the construction space, HCC is looking for buy outs in Europe and Middle East. It may be noted that the company had acquired the controlling stake in Swiss developer Karl Steiner AG earlier this year. HCC is targeting an acquisition ticket size of atleast US$ 100 m. The company also wants to boost its presence in toll roads from its current six projects. This is when NHAI is looking to open bids for around 6,000 kms by March FY11. It is expected that HCC will bid for at least 3 to 4 national highway projects over the next six months, each worth between US$ 1.5 bn to US$ 2 bn.
However, it may be noted that HCC has one of the highest debt/equity ratios in the industry. As of FY10 this ratio stood at 1.7x. Since HCC has higher share of hydro power projects which typically have a long gestation period, the working capital requirements of the company are above industry average. It comes as no surprise that a large portion of the company's debt has been taken to fund working capital requirements.
Moving on to news from the finance sector, infrastructure lender, IDFC is looking to raise Rs 34 bn via public issue of infrastructure bonds. The bond issue proceeds would be utilised to finance the infrastructure projects in the country. Currently, IDFC allocates 40% of its corpus to the energy, 24% to telecoms, 20% for transportation and remaining for other infra sectors. It may be noted that Infrastructure Finance companies (IFCs) can now raise external commercial borrowings (ECBs) up to 50% of their networth under the automatic route. IDFC has a networth of Rs 100 bn. The company had already raised Rs 20 bn through ECB in the current fiscal and this leaves further scope to raise Rs 30 bn. The company is looking to raise this amount overseas.
In news from the banking sector, ICICI which has been a laggard in terms of growing its balance sheet over the past two fiscals, is looking at making up for the same in FY12. The bank is targeting loan growth of 12% this fiscal, it is targeting a growth of 20% to 22% in FY12. This is marginally higher than the expected sector growth. The bank which, in fact, had to cut down on its retail portfolio over the past two fiscals due to NPA risks, is seeing a strong loan growth from retail and corporate segments. ICICI Bank has also suffered from lower fee income in recent quarters and hopes to improve its other income contribution as well this year.
Coming to news from the healthcare space, Lupin Ltd's Netherlands-based wholly-owned subsidiary, Lupin Holdings BV (LHBV) has acquired an additional 7% stake in Australia's Generic Health Pty Ltd for an undisclosed amount. This brings the company's holding in Generic Health to 57%. Generic Health supplies generic medicines to pharmacists and hospitals all over Australia at a low costs. It has various partnerships with international drug manufacturers.
Australia is a strategic market for Lupin and is valued at US$ 9 bn. Out of this the share of generics is over US$ 1 bn. This provides Lupin a major opportunity. The company has built up a sizable amount of product pipeline in therapeutic areas of heart ailments, diabetes and over the counter products, specially intended for the Australian market and has filed approvals for many of these products with the Australian authorities.
Company | 23-Sep-10 | 1-Oct-10 | Change | 52-wk High/Low | |
Top gainers during the week (BSE-A Group) | |||||
Unitech | 85 | 94 | 11.7% | 109 / 67 | |
Cadila Healthcare | 626 | 697 | 11.4% | 681 / 320 | |
GSK Pharma | 2,021 | 2,249 | 11.3% | 2,285 / 1,455 | |
LIC Housing | 1,310 | 1,450 | 10.7% | 1,497 / 705 | |
Glenmark Pharma | 284 | 312 | 9.8% | 307 / 219 | |
Top losers during the week (BSE-A Group) | |||||
Financial Tech. | 1,398 | 1,184 | -15.3% | 1,722 / 1,100 | |
IRB Infra. | 290 | 266 | -8.2% | 313 / 207 | |
Jain Irrigation | 1,260 | 1,170 | -7.1% | 1,320 / 733 | |
Tata Comm. | 327 | 308 | -5.5% | 499 / 233 | |
HPCL | 540 | 513 | -5.0% | 555 / 298 |
Food inflation rose for the fifth straight week rising by 1% YoY to 16.4% for the week ending September 18. The reason for this was the increase in cost of cereals, fruits, some vegetables and milk on account of supply disruptions and heavy rains and floods. However, the finance minister Mr Pranab Mukherjee has stated that he expects some moderation in prices now that the monsoon period is over.
For information on how to pick stocks that have the potential to deliver big returns, download our special report now!
Read the latest Market Commentary
Equitymaster requests your view! Post a comment on "European concerns weigh on markets". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!